Cargando…

SIL-TAL1融合基因阳性急性T淋巴细胞白血病19例临床分析

OBJECTIVE: To assess the clinical characteristics and prognosis of patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia(T-ALL). METHODS: The clinical data of 19 SIL-TAL1-positive T-ALL patients admitted to the First Affiliated Hospital of Soochow University between January 2014 and Fe...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033260/
https://www.ncbi.nlm.nih.gov/pubmed/36948867
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.02.008
Descripción
Sumario:OBJECTIVE: To assess the clinical characteristics and prognosis of patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia(T-ALL). METHODS: The clinical data of 19 SIL-TAL1-positive T-ALL patients admitted to the First Affiliated Hospital of Soochow University between January 2014 and February 2022 were retrospectively computed and contrasted with SIL-TAL1-negative T-ALL patients. RESULTS: The median age of the 19 SIL-TAL1-positive T-ALL patients was 15(7 to 41 years), including 16 males(84.2%). SIL-TAL1-positive T-ALL patients had younger age, higher WBC, and hemoglobin compared with SIL-TAL1-negative T-ALL patients. There was no discrepancy in gender distribution, PLT, chromosome abnormality distribution, immunophenotyping, and complete remission(CR)rate. The 3-year overall survival(OS)was 60.9% and 74.4%, respectively(HR=2.070, P=0.071). The 3-year relapse-free survival(RFS)was 49.2% and 70.6%, respectively(HR=2.275, P=0.040). The 3-year RFS rate of SIL-TAL1-positive T-ALL patients was considerably lower than SIL-TAL1-negative T-ALL patients. CONCLUSION: SIL-TAL1-positive T-ALL patients were connected to younger age, higher WBC, higher HGB, and poor outcome.